The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022.
- Advertising -
Access Sample Report : bit.ly/2jIGOKN
Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market.
Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.
The world asthma and COPD drugs market is segmented based on disease and medication class and geography.
- Advertising -
On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others.
And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
- The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
- The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
- Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
- Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
Enquire About Report : bit.ly/2z9dgJ5
Key market segments
- The world COPD and asthma drug market is segmented by medication class, disease and geography.
MARKET BY DISEASES
MARKET BY MEDICATION CLASS
- Combination Products
- Relvar/Breo Ellipta
- Leukotriene Antagonists (LTA)
Access Report : bit.ly/2Ba6e8q
- Inhaled Corticosteroids (ICS)
- Short Acting Beta Agonists(SABA)
- Long Acting Beta Agonists (LABA)
MARKET BY GEOGRAPHY
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Middle East
- GlaxoSmithKline (GSK)
- Novartis AG.
- Merck & Co.
- Abbott Laboratories.
- Boehringer Ingelheim.
- Roche Holding AG
- Teva Pharmaceutical Industries.
- Vectura Group
Other players in the value chain include (profiles not included in the report)
- Aerovance Inc.
- Alkermes Inc.
- Almirall SA
- Genentech Inc.
- Sepracor, Inc.
- Skyepharma plc
Table Of Content
- CHAPTER 1 INTRODUCTION
- CHAPTER 2 EXECUTIVE SUMMARY
- CHAPTER 3 MARKET OVERVIEW
- CHAPTER 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE
- CHAPTER 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS
- CHAPTER 6 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022
- CHAPTER 7 GLOBALASTHMA AND COPD DRUGS PIPELINE -2015
- CHAPTER 8 COMPANY PROFILES
Category: Market Research Publishers and RetailersCompany about: We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities. In order to survive the fierce competition and locate different avenues, one must be privy to high end and quality market information. So, we try and provide you with latest market information by getting high market research reports fro ...